Related Experiment Video
Updated: Aug 10, 2026
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
Published on: June 7, 2015
Comprehensive Characterization via Molecular Imaging, Longitudinal Multisite Sampling, and Autoptic Work-up in
Johanna S Enke1, Nic G Reitsam2,3, Sebastian Dintner4,3
1Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
Abstract:
Despite the addition of immune checkpoint blockade to first-line chemotherapy, the prognosis for patients with small cell lung cancer (SCLC) is still devastating. For the subset of SCLC with somatostatin receptor (SSTR) overexpression, radiopharmaceutical therapy (RPT) might be an effective future treatment option. Methods: Here, we present the case of a heavily pretreated stage IV SCLC patient showing an exceptional response to SSTR-directed RPT. A comprehensive translational work-up consisting of histopathologic, immunohistochemical, and molecular pathology analyses at different time points during treatment and especially of lesions with discordant tracer uptake was performed. Results: Besides a promising response to RPT, interesting signs of clonal dynamics under therapy and, most importantly, SSTR downregulation of some lesions as a potential evasion mechanism to SSTR-directed RPT could be identified. Conclusion: This unique investigation for a clinical-molecular understanding of novel treatment paradigms in SCLC may provide the basis for future treatment designs.
Insights
Radiopharmaceutical therapy (RPT) shows promise for small cell lung cancer (SCLC) patients with somatostatin receptor (SSTR) overexpression. This case study highlights an exceptional response and identifies potential SSTR downregulation as an evasion mechanism.
Area of Science:
- Oncology
- Nuclear Medicine
- Translational Research
Background:
- Small cell lung cancer (SCLC) has a poor prognosis despite current treatments.
- Immune checkpoint inhibitors offer limited benefit as a first-line therapy for SCLC.
- Somatostatin receptor (SSTR) overexpression in a subset of SCLC patients presents a potential therapeutic target.
Purpose of the Study:
- To investigate the efficacy of SSTR-directed radiopharmaceutical therapy (RPT) in a heavily pretreated stage IV SCLC patient.
- To explore the clinical and molecular dynamics of SCLC response to RPT.
- To identify potential mechanisms of resistance to SSTR-targeted therapy.
Main Methods:
- Case presentation of a stage IV SCLC patient undergoing SSTR-directed RPT.
- Comprehensive translational analysis including histopathology, immunohistochemistry, and molecular pathology.
- Longitudinal assessment of treatment response and tumor characteristics, focusing on discordant SSTR uptake lesions.
Main Results:
- The patient exhibited an exceptional response to SSTR-directed RPT.
- Evidence of clonal evolution and dynamics within the tumor during therapy was observed.
- Downregulation of SSTR in specific lesions was identified as a potential resistance mechanism to RPT.
Conclusions:
- SSTR-directed RPT demonstrates significant potential as a future treatment for SCLC with SSTR overexpression.
- Understanding tumor clonal dynamics and resistance mechanisms like SSTR downregulation is crucial for optimizing RPT strategies.
- This study provides a foundation for developing novel, personalized treatment designs for SCLC.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
08:54Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
